Health Care/Hospital

Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®

The company's proven ability to reduce symptoms of occasional depression with Affron®, and its strong focus on quality control, have helped it deliver a truly outstanding product LONDON, March 23, 2021 /PRNewswire/ -- Based on its recent analysis of the North American market for industrial enter...

2021-03-23 20:00 1170

Pharma Industry to Spend $4.5 Billion on Digital Transformation by 2030

While the creation, manufacture, and supply of COVID vaccines are grabbing attention, behind the scenes, pharma manufacturers are digitizing at pace LONDON, March 23, 2021 /PRNewswire/ -- Pharma 4.0 concepts are taking hold in pharmaceutical manufacturing. The industry's unique characteristics ar...

2021-03-23 16:00 1284

Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)

PARIS, March 23, 2021 /PRNewswire/ -- Unither Pharmaceuticals, the Blow-Fill-Seal (BFS) worldwide leader, provides diagnostic companies with capacity solutions and innovative technologies for their testing kits (Covid, Flu, etc.).

2021-03-23 15:04 1970

Taiko Pharmaceutical Officially Launches "Cleverin" in Mexico, Top Made-in-Japan Brand for Removing Viruses/Bacteria, Deodorization

OSAKA, Japan, March 23, 2021 /PRNewswire/ -- Together with a local distribution partner, Torishi S.A. de C.V., Taiko Pharmaceutical Co., Ltd. (hereinafter Taiko), based inOsaka, Japan, has announced the launch of "Cleverin," a top made-in-Japan brand (*1) among products for removing viruses/bacte...

2021-03-23 14:00 3219

Shockwave Announces Joint Venture In China with Genesis MedTech Group

SINGAPORE, March 23, 2021 /PRNewswire/ -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has signed an agreement to form a joint venture with Genesis MedTe...

2021-03-23 11:38 8065

CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary

* Marks vaccine's first approval by an European Union member state, following Mexico, Pakistan and China * Continues to boost production capacity to meet increasing demand * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effectiv...

2021-03-23 00:43 3623

PathogenDx Applauded by Frost & Sullivan for Its Ultra-rapid COVID-19 Testing Platform, DetectX-Rv Test

PathogenDx's disruptive nucleic acid-based test uses a multiplex microarray to rapidly identify, detect, and quantify multiple pathogens and viral strains SANTA CLARA, Calif., March 22, 2021 /PRNewswire/ -- Based on its recent analysis of the global molecular testing market,Frost & Sullivan recog...

2021-03-22 22:00 1552

Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages

SINGAPORE, March 22, 2021 /PRNewswire/ -- Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers and COVID-19's post-recovery complications, which include heart damage, diabetes and multi-system ...

2021-03-22 21:00 1616

Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma

WOBURN, Mass., March 22, 2021 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90...

2021-03-22 20:30 1356

Insightful Science Joins Forces with Dotmatics to Form a Leading Cloud-First Scientific R&D Company

- Combined company will generate well over $100 million of ARR and signals a significant transformation in the future of software and data management in research labs. - Enabling over one million scientists to improve research and lab efficiency. - Facilitating rapid data access and exchange bet...

2021-03-22 19:03 3033

RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib[1] treatment on an...

2021-03-22 19:00 3038

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020

SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-03-22 15:06 2560

Xinhua Silk Road: Nanjing Jiangbei New Area invites global partners to jointly promote dev. of life and health industry

BEIJING, March 22, 2021 /PRNewswire/ -- Nanjing Jiangbei New Area, a state-level new area in eastChina's Jiangsu Province, sent invitation to global investors to enterChina's buoyant life and health market, according to a promotion meeting held recently inShanghai. At present, the new pharmaceut...

2021-03-22 14:45 2343

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-03-22 10:40 3190

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

SHANGHAI and SUZHOU, China, March 22, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2). This study w...

2021-03-22 10:31 4211

Airly raises $3.3m from marquee tech investors to address the air quality health crisis

- Problem: More than 10 million people die each year from air pollution - Solution: Airly's sensors and software provide ultra-local, accurate, predictive air quality data to help control air pollution across the world  - Traction: Revenue increased over 200% outside the home market in 2020 with ...

2021-03-22 09:00 3729

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

SHANGHAI and GAITHERSBURG, Md., March 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematolog...

2021-03-22 08:00 2513

Innoforce Pharmaceuticals Completes 625M CNY ($96M) Series A Financing

HANGZHOU, China, March 22, 2021 /PRNewswire/ -- Innoforce Pharmaceuticals ("INF"), a biopharmaceutical innovation and partnership company, announced today the completion of a625M CNY ($96M) Series A financing, which follows a 170M CNY ($24M) Pre-A financing completed in June 2020. The Series A ...

2021-03-22 08:00 3780

Ocumension Therapeutics (1477.HK) Reports Revenue Growth in 2020, National Commercial Construction has been started to become outstanding

HONG KONG, March 20, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended31 December 2020 today. Ocumension The...

2021-03-20 18:20 8487

Qiming's Portfolio Company Connect Biopharma Lists on Nasdaq

SHANGHAI, March 20, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price isUS$ 17.00/ADS. The stock opened at US$19.55/ADS and closed atUS$18.49/ADS on the first trading day, up 8.8%, with a market...

2021-03-20 09:00 15235
1 ... 352353354355356357358 ... 553